These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 14671402)

  • 1. Glucocorticoid-induced osteoporosis.
    Compston J
    Horm Res; 2003; 60 Suppl 3():77-9. PubMed ID: 14671402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options.
    De Nijs RN
    Minerva Med; 2008 Feb; 99(1):23-43. PubMed ID: 18299694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of glucocorticoid-induced osteoporosis.
    van Brussel MS; Bultink IE; Lems WF
    Expert Opin Pharmacother; 2009 Apr; 10(6):997-1005. PubMed ID: 19351276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucocorticoid-induced osteoporosis: pathogenesis, diagnosis, and management.
    McIlwain HH
    Prev Med; 2003 Feb; 36(2):243-9. PubMed ID: 12591000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of bisphosphonates and dual-energy X-ray absorptiometry scans in the prevention and treatment of glucocorticoid-induced osteoporosis in rheumatology.
    Wall E; Walker-Bone K
    QJM; 2008 Apr; 101(4):317-23. PubMed ID: 18270228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucocorticoid induced risk of fractures.
    Maruotti N; Corrado A; Cantatore FP
    Panminerva Med; 2010 Dec; 52(4):339-43. PubMed ID: 21183894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucocorticoid-induced osteoporosis.
    Berris KK; Repp AL; Kleerekoper M
    Curr Opin Endocrinol Diabetes Obes; 2007 Dec; 14(6):446-50. PubMed ID: 17982350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of Oral Bisphosphonates in Reducing Fracture Risk Among Oral Glucocorticoid Users: Three Matched Cohort Analyses.
    Amiche MA; Lévesque LE; Gomes T; Adachi JD; Cadarette SM
    J Bone Miner Res; 2018 Mar; 33(3):419-429. PubMed ID: 29068496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secondary osteoporosis: underlying disease and the risk for glucocorticoid-induced osteoporosis.
    Boling EP
    Clin Ther; 2004 Jan; 26(1):1-14. PubMed ID: 14996513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucocorticoid-induced osteoporosis: an update.
    Compston J
    Endocrine; 2018 Jul; 61(1):7-16. PubMed ID: 29691807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical question: What is the best approach to managing glucocorticoid-induced osteoporosis?
    Compston J
    Clin Endocrinol (Oxf); 2011 May; 74(5):547-50. PubMed ID: 21470278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Secondary osteoporosis or secondary contributors to bone loss in fracture. Therapeutic strategy for glucocorticoid-induced osteoporosis].
    Hayakawa N; Suzuki A
    Clin Calcium; 2013 Sep; 23(9):1337-44. PubMed ID: 23999371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skeletal morbidity in inflammatory bowel disease.
    van Hogezand RA; Hamdy NA
    Scand J Gastroenterol Suppl; 2006; (243):59-64. PubMed ID: 16782623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucocorticoid-induced osteoporosis.
    de Gregório LH; Lacativa PG; Melazzi AC; Russo LA
    Arq Bras Endocrinol Metabol; 2006 Aug; 50(4):793-801. PubMed ID: 17117304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early use of alendronate as a protective factor against the development of glucocorticoid-induced bone loss in childhood-onset rheumatic diseases: a cross-sectional study.
    Inoue Y; Mitsunaga K; Yamamoto T; Chiba K; Yamaide F; Nakano T; Morita Y; Yamaide A; Suzuki S; Arima T; Yamaguchi KI; Tomiita M; Shimojo N; Kohno Y
    Pediatr Rheumatol Online J; 2018 Jun; 16(1):36. PubMed ID: 29914510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid-induced bone loss in patients with inflammatory rheumatic diseases. A randomized study.
    Cortet B; Hachulla E; Barton I; Bonvoisin B; Roux C
    Rev Rhum Engl Ed; 1999 Apr; 66(4):214-9. PubMed ID: 10339777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An update on glucocorticoid-induced osteoporosis.
    Woolf AD
    Curr Opin Rheumatol; 2007 Jul; 19(4):370-5. PubMed ID: 17551369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucocorticoid-induced osteoporosis and its treatment.
    Pennisi P; Trombetti A; Rizzoli R
    Clin Orthop Relat Res; 2006 Feb; 443():39-47. PubMed ID: 16462424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of bone metabolism during early stage and clinical benefits of early intervention with alendronate in patients with systemic rheumatic diseases treated with high-dose glucocorticoid: Early DIagnosis and Treatment of OsteopoRosis in Japan (EDITOR-J) study.
    Tanaka Y; Mori H; Aoki T; Atsumi T; Kawahito Y; Nakayama H; Tohma S; Yamanishi Y; Hasegawa H; Tanimura K; Negoro N; Ueki Y; Kawakami A; Eguchi K; Saito K; Okada Y
    J Bone Miner Metab; 2016 Nov; 34(6):646-654. PubMed ID: 26308708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Glucocorticoid and bone].
    Soen S
    Clin Calcium; 2014 Jun; 24(6):829-36. PubMed ID: 24870833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.